• TITAN PRODUCT CANDIDATES
• Probuphine^®
• Other Clinical Development Opportunities
• PARTNERED PRODUCT
  CANDIDATES

Partnered Product Candidates

Fanapt™ (iloperidone)

Fanapt™ is an atypical antipsychotic approved by the US FDA on May 6, 2009 for the treatment of schizophrenia. Fanapt’s™ unique binding profile to dopamine and serotonin receptors may potentially provide a highly differentiated treatment for patients suffering from schizophrenia. The global commercialization rights to Fanapt™ are licensed to Vanda Pharmaceuticals, Inc. and Vanda has announced that Fanapt™ will be available in pharmacies later in 2009. Titan is entitled to receive royalties on global net sales of Fanapt™ equal to 8% on annual net sales up to $200 million, and 10% on annual net sales above $200 million. Titan incurs no ongoing expenses associated with this royalty income that may potentially commence by the end of 2009.